🎁 Black Friday: up to 50% off of annual plans
CDT Equity Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
0.2300
-0.0371 (-13.89%)
At close: Nov 20, 2026, 4:00 PM EST
0.2400
+0.0100 (4.35%)
After-hours: Nov 20, 2026, 7:55 PM EST

Company Description

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets.

The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health.

The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025.

The company was founded in 2019 and is based in Naples, Florida.

CDT Equity Inc.
CDT Equity logo
CountryUnited States
Founded2019
IndustryBiotechnology
SectorHealthcare
Employees4
CEOJames Bligh

Contact Details

Address:
4581 Tamiami Trail North, Suite 200
Naples, Florida 34103
United States
Phone646 491 9132
Websitecdtequity.com

Stock Details

Ticker SymbolCDT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1896212
CUSIP Number20678X809
ISIN NumberUS20678X8092
Employer ID87-3272543
SIC Code2834

Key Executives

NamePosition
James BlighCo-Founder, Chief Executive Officer, Chief Financial Officer and Director
Dr. Joanne M. HollandChief Scientific Officer
Dr. David Joszef TapolczayHead of Strategy and Licensing

Latest SEC Filings

DateTypeTitle
Nov 17, 2026424B3Prospectus
Nov 16, 202610-QQuarterly Report
Nov 16, 2026424B3Prospectus
Nov 16, 20268-KCurrent Report
Nov 9, 2026424B3Prospectus
Nov 9, 20268-KCurrent Report
Nov 6, 2026SCHEDULE 13D/AFiling
Nov 4, 2026424B3Prospectus
Nov 4, 20268-KCurrent Report
Nov 3, 2026424B3Prospectus